Executive interview – ROVI

Executive interview – ROVI

Laboratorios Farmacéuticos ROVI is a fully integrated, profitable Spanish pharmaceutical company established in 1946 which listed on the Madrid Stock Exchange in 2007. ROVI is involved in the research and development, in-licensing, manufacture and marketing of small molecule and speciality biologic drugs. ROVI has a particular expertise in low molecular weight heparins (LMWH), with internally developed assets Hibor (bemiparin) and Becat (enoxaparin biosimilar) being key drivers of near-term revenue and profit growth. Sustainable long-term growth is dependent on successful R&D investment and ROVI’s efforts here lie in its ISM (in situ microimplants) technology. In this video, the company’s vice president & chief financial officer Javier López-Belmonte introduces the company, its LMWH franchise and an overview the commercialisation strategy for with its Phase III asset DORIA (Risperidone ISM).


You may also be interested in these:

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free